Etravirine
- Generic Name
- Etravirine
- Brand Names
- Intelence
- Drug Type
- Small Molecule
- Chemical Formula
- C20H15BrN6O
- CAS Number
- 269055-15-4
- Unique Ingredient Identifier
- 0C50HW4FO1
- Background
Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HI...
- Indication
Etravirine is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in treatment-experienced patients ≥2 years of age.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT04208373
- Locations
- 🇧🇪
SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg), Antwerpen, Belgium
Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- Target Recruit Count
- 30
- Registration Number
- NCT02818348
- Locations
- 🇪🇸
Fundació Lluita contra la SIDA, Badalona, Barcelona, Spain
Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine
- Conditions
- Interventions
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2013-06-13
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 33
- Registration Number
- NCT01876966
A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
- Conditions
- Interventions
- Drug: Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)Drug: Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableDrug: DarunavirDrug: Emtricitabine/tenofovir disoproxil fumarateOther: SOC adherence versus SOC+CPI adherenceDrug: EtravirineDrug: Raltegravir
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2019-03-15
- Target Recruit Count
- 545
- Registration Number
- NCT01641367
- Locations
- 🇧🇷
Hospital Nossa Senhora da Conceicao CRS (12201), Porto Alegre, RS, Brazil
🇧🇷Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇮🇳Chennai Antiviral Research and Treatment (CART) CRS (11701), Chennai, Taramani, India
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
- First Posted Date
- 2011-08-23
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- Janssen R&D Ireland
- Target Recruit Count
- 211
- Registration Number
- NCT01422330
A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 108
- Registration Number
- NCT01254656
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients
- Conditions
- Interventions
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Tibotec, Inc
- Target Recruit Count
- 54
- Registration Number
- NCT01199939
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
- Conditions
- Interventions
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 30
- Registration Number
- NCT01199731
- Locations
- 🇷🇴
GSK Investigational Site, Constanta, Romania
Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once Daily
- Conditions
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2011-02-08
- Lead Sponsor
- Hospitales Universitarios Virgen del Rocío
- Target Recruit Count
- 16
- Registration Number
- NCT01121809
- Locations
- 🇪🇸
Hospitales Universitarios Virgen del Rocio, Sevilla, Spain
TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients
- First Posted Date
- 2010-03-22
- Last Posted Date
- 2012-12-11
- Lead Sponsor
- Tibotec Pharmaceuticals, Ireland
- Target Recruit Count
- 49
- Registration Number
- NCT01090648
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.